Biotechnology - Biotechnology, Dermatologicals


Popular Filters

Positive Ph III results with oral Otezla in skin, nail and scalp of patients with plaque psoriasis


US biotech firm Celgene has released positive new research findings on Otezla (apremilast), an oral,…


US FDA clears Xolair for chronic idiopathic urticaria


Swiss drug major Novartis says the US Food and Drug Administration has approved Xolair (omalizumab) for…

BiotechnologyDermatologicalsGenentechNorth AmericaNovartisRegulationRocheUSAXolair

Systemic psoriasis market forecast to reach $10.4 billion by 2020


The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015


Psoriasis drug Stelara (ustekinumab), from US health care giant Johnson & Johnson’s subsidiary Janssen…

BiotechnologyDermatologicalsJanssen BiotechMarkets & MarketingStelara InjectionUSA

Galapagos in deal with Biogen Idec for scleroderma research

Galapagos in deal with Biogen Idec for scleroderma research


Belgian biotech firm Galapagos says that a subsidiary has signed a three-year collaboration agreement…

Biogen IdecBiotechnologyDermatologicalsGalapagosLicensingResearch

Rigel sees clear forward path for fostamatinib but will drop R333


Clinical-stage US drug developer Rigel Pharmaceuticals has announced mixed updates on two of its pipeline…

BiotechnologyDermatologicalsfostamatinibImmunologicalsR333RegulationResearchRigel Pharmaceuticals

NovaBiotics enters co-development agreement for Novexatin


Scotland-headquartered clinical-stage biotech firm NovaBiotics has entered into an exclusive agreement…

BiotechnologyDermatologicalsLicensingNovaBioticsNovexatinTaro Pharmaceuticals

Actelion bid for Ceptaris looks secured as FDA approves Valchlor


Privately-held USA-based Ceptaris Therapeutics revealed yesterday (August 26) that the US Food and Drug…

ActelionBiotechnologyCeptaris TherapeuticsDermatologicalsMergers & AcquisitionsNorth AmericaRegulationValchlor

First in class novel biologic for psoriasis launched in India


Bangalore, India-based Biocon (BSE: 532523), Asia's premier biotechnology company, has launched its 'first…

ALZUMAbAsia-PacificBioconBiotechnologyDermatologicalsitolizumabMarkets & Marketing

Swedish Pergamum reports positive preliminary efficacy results of LL-37 in chronic leg ulcers


Pergamum, a portfolio company of Sweden-based investment company Karolinska Development, says that the…

BiotechnologyDermatologicalsKarolinska DevelopmentResearch

Sandoz initiates Ph III trial for biosimilar Enbrel


Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…


AAD conference briefs: Celgene's apremilast; and Sanofi's dupilumab


The European subsidiary of US biotech firm Celgene Corp (Nasdaq: CELG) presented the results from ESTEEM…


LEO Pharma and 4SC Discovery link for skin disease research


Privately-held Danish dermatology specialist LEO Pharma has entered into an exclusive research and license…

4SC DiscoveryBiotechnologyDermatologicalsLEO PharmaLicensingPharmaceuticalResearch

Genentech Ph III study of omalizumab shows promise in CIU


Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

PharmaEssentia gets certain Asian rights to Kinex' dermatology candidate KX01


USA-based privately-held Kinex Pharmaceuticals has entered a licensing agreement granting Taiwan's PharmaEssentia…

Asia-PacificBiotechnologyDermatologicalsKinex PharmaceuticalsKX01LicensingPharmaEssentia

RegeneRx explores strategic options


US biotech firm RegeneRx Biopharmaceuticals. (OTC Bulletin Board: RGRX) revealed yesterday that it has…


LEO Pharma in over $300 million deal for psoriasis therapy


Privately-held Danish drugmaker LEO Pharma A/S has signed a multi-million dollar in-licensing deal with…

BiotechnologyDermatologicalsLEO PharmaLicensingPharmaceuticalVirobay

Back to top